Last verified: May 2026
The Sponsors
- Sen. Mary Felzkowski (R-Tomahawk) — Senate President; cancer survivor; the Senate’s leading medical-cannabis advocate.
- Sen. Patrick Testin (R-Stevens Point) — Senate President Pro Tempore.
- Rep. Patrick Snyder (R-Weston) — Assembly companion sponsor.
The all-Republican sponsorship is notable: the leading medical-cannabis advocacy in Wisconsin has come from Republican legislators in the central / northern part of the state, a contrast with Democratic legalization efforts coming from Madison and Milwaukee.
What SB 534 Does
- Creates Office of Medical Cannabis Regulation under DHS.
- Private licensed growers, processors, labs, and dispensaries (in contrast with Rep. Plumer’s 2024 state-run-dispensary proposal).
- Qualifying conditions: cancer, glaucoma, IBD, MS, PTSD, seizures, chronic pain, severe muscle spasms, severe chronic nausea.
- No smokable forms — oral, topical, and other non-combustion routes only.
- Patient-registration framework with practitioner certification.
- State excise tax structure (proposed but not finalized in committee).
The October 22, 2025 Senate Health Committee Hearing
The Senate Health Committee held a public hearing on October 22, 2025. Testimony was overwhelmingly in support — patient advocates, medical professionals, family members of patients with qualifying conditions. The Senate Health Committee advanced SB 534 on a 4-1 vote.
The Senate Floor Stall
As of May 2026, SB 534 has not received a Senate floor vote. The bill is in legislative limbo. Senate Majority Leader Devin LeMahieu (R-Oostburg) had previously called state-run dispensaries "nonstarter" but supported private-licensed structure. The floor-vote delay reflects:
- Republican-coalition uncertainty about timing.
- Speaker Vos’s Assembly-side opposition (called the bill "way too broad and way too wide-ranging").
- Strategic positioning ahead of November 2026 elections.
- Whether the bill could pass the Assembly even if it cleared the Senate.
Speaker Vos’s "Way Too Broad" Framing
Speaker Robin Vos (R-Rochester) has been the principal Republican opponent of cannabis-policy reform for years. His "way too broad" assessment of SB 534 — despite SB 534 being more restrictive than Evers’s budget proposals or Sen. Agard’s legalization bills — signals that any non-CBD-only medical-cannabis bill faces Assembly resistance. Vos in December 2023 called cannabis a "dangerous drug." His 2026 retirement removes one of the principal Republican obstacles to reform but does not guarantee Assembly passage of medical cannabis.
The Cabral-Guevara Health Committee Chair
Senate Health Committee Chair Sen. Rachael Cabral-Guevara (R-Appleton), a nurse practitioner, held the SB 534 hearing. Her committee’s 4-1 advancement of the bill demonstrates Republican-side openness to medical cannabis at the committee level.
The 2026 Inflection
SB 534’s fate depends on:
- Whether the Senate floor takes a vote before the 2025-2027 session ends.
- Whether the Assembly takes up the bill (Speaker Vos’s posture suggests not).
- The 2026 election outcome — new GOP and Democratic leadership.
- Whether a 2027-2029 session restarts the bill with new sponsors and new context.
The 2026 outlook: medical cannabis through SB 534 in 2026 is uncertain; medical cannabis in 2027 is more likely under a Democratic-trifecta scenario.
Why SB 534 Matters Beyond Wisconsin
SB 534 is one of the more carefully-designed medical-cannabis bills introduced in a Republican-controlled Midwest state in recent years. Its eventual fate signals broader patterns:
- Whether Republican-leadership-introduced bills can pass.
- Whether private vs. state-run distribution preferences resolve.
- Whether the no-smokable-flower compromise becomes the regional standard.
- Whether the 2026 election produces a Democratic trifecta that makes adult-use possible.
For in-depth cannabis education, dosing guides, safety information, and research summaries, visit our partner site TryCannabis.org
Related on this site: Evers Budgets, Lydia’s Law (CBD-only), Send a Message.